7-chloro-N-cyclohexyl-1-oxido-1,2,4-benzotriazin-1-ium-3-amine | 921933-36-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 7-chloro-N-cyclohexyl-1-oxido-1,2,4-benzotriazin-1-ium-3-amine
• CAS: 921933-36-0
• 化学式: C₁₃H₁₅ClN₄O
• 分子量: 278.741
• InChiKey: AHRLGGARZUQEEE-UHFFFAOYSA-N

物化性质

• 沸点：
  476.3±37.0 °C(Predicted)
• 密度：
  1.48±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.66
• 重原子数：
  19.0
• 可旋转键数：
  2.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  64.75
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  7-chloro-N-cyclohexyl-1-oxido-1,2,4-benzotriazin-1-ium-3-amine 在 双氧水 、 溶剂黄146 作用下， 以45.8%的产率得到7-chloro-3-(cyclohexylamino)benzo[e][1,2,4]triazine 1,4-dioxide
  参考文献：
  名称：

  3-Amino-1,2,4-benzotriazine-1,4-dioxide 衍生物的合成、结构和缺氧细胞毒性

  摘要：

  合成了一系列新型 3-氨基-1,2,4-苯并三嗪-1,4-二氧化物衍生物并筛选了它们对早幼粒细胞白血病HL-60、雄激素非依赖性前列腺肿瘤PC3、肝细胞癌Bel-7402的体外细胞毒性、人食道肿瘤 ECA-109 和人乳腺肿瘤 MCF-7 细胞系在缺氧和常氧条件下。大多数化合物在缺氧和常氧条件下都显示出更高的细胞毒活性。其中，与替拉扎明相比，化合物 61 和 62 显示出更有效的细胞毒活性和低氧选择性。

  DOI：

  10.1002/ardp.200600201
• 作为产物：
  描述：

  N-(4-氯-2-硝基苯基)乙酰胺 在 盐酸 、 三乙胺 、 三氟乙酸 、 sodium nitrite 、 三氯氧磷 作用下， 以 乙醚 、 二氯甲烷 、 水 为溶剂， 反应 11.0h， 生成 7-chloro-N-cyclohexyl-1-oxido-1,2,4-benzotriazin-1-ium-3-amine
  参考文献：
  名称：

  Discovery and Optimization of Benzotriazine Di-N-Oxides Targeting Replicating and Nonreplicating Mycobacterium tuberculosis

  摘要：

  Compounds bactericidal against both replicating and nonreplicating Mtb may shorten the length of TB treatment regimens by eliminating infections more rapidly. Screening of a panel of antimicrobial and anticancer drug classes that are bioreduced into cytotoxic species revealed that 1,2,4-benzotriazine di-N-oxides (BTOs) are potently bactericidal against replicating and nonreplicating Mtb. Medicinal chemistry optimization, guided by semiempirical molecular orbital calculations, identified a new lead compound (20q) from this series with an MIC of 0.31 mu g/mL against H37Rv and a cytotoxicity (CC50) against Vero cells of 25 mu g/mL. 20q also had equivalent potency against a panel of single-drug resistant strains of Mtb and remarkably selective activity for Mtb over a panel of other pathogenic bacterial strains. 20q was also negative in a L5178Y MOLY assay, indicating low potential for genetic toxicity. These data along with measurements of the physiochemical properties and pharmacokinetic profile demonstrate that BTOs have the potential to be developed into a new class of antitubercular drugs.

  DOI：

  10.1021/jm300123s

文献信息

• Synthesis, Structure and Hypoxic Cytotoxicity of 3-Amino-1,2,4-benzotriazine-1,4-dioxide Derivatives
  作者：Faqin Jiang、Qinjie Weng、Rong Sheng、Qing Xia、Qiaojun He、Bo Yang、Yongzhou Hu

  DOI：10.1002/ardp.200600201

  日期：2007.5

  3‐amino‐1,2,4‐benzotriazine‐1,4‐dioxide derivatives were synthesized and screened for their in vitro cytotoxicity against promyelocytic leukemia HL‐60, androgen‐independent prostate tumor PC3, hepatocellular carcinoma Bel‐7402, human esophagus tumor ECA‐109, and human breast tumor MCF‐7 cell lines in hypoxia and in normoxia. Most compounds showed higher cytotoxic activity both in hypoxia and in normoxia

  合成了一系列新型 3-氨基-1,2,4-苯并三嗪-1,4-二氧化物衍生物并筛选了它们对早幼粒细胞白血病HL-60、雄激素非依赖性前列腺肿瘤PC3、肝细胞癌Bel-7402的体外细胞毒性、人食道肿瘤 ECA-109 和人乳腺肿瘤 MCF-7 细胞系在缺氧和常氧条件下。大多数化合物在缺氧和常氧条件下都显示出更高的细胞毒活性。其中，与替拉扎明相比，化合物 61 和 62 显示出更有效的细胞毒活性和低氧选择性。
• Discovery and Optimization of Benzotriazine Di-<i>N</i>-Oxides Targeting Replicating and Nonreplicating Mycobacterium tuberculosis
  作者：Sidharth Chopra、Gary A. Koolpe、Arlyn A. Tambo-ong、Karen N. Matsuyama、Kenneth J. Ryan、Tran B. Tran、Rupa S. Doppalapudi、Edward S. Riccio、Lalitha V. Iyer、Carol E. Green、Baojie Wan、Scott G. Franzblau、Peter B. Madrid

  DOI：10.1021/jm300123s

  日期：2012.7.12

  Compounds bactericidal against both replicating and nonreplicating Mtb may shorten the length of TB treatment regimens by eliminating infections more rapidly. Screening of a panel of antimicrobial and anticancer drug classes that are bioreduced into cytotoxic species revealed that 1,2,4-benzotriazine di-N-oxides (BTOs) are potently bactericidal against replicating and nonreplicating Mtb. Medicinal chemistry optimization, guided by semiempirical molecular orbital calculations, identified a new lead compound (20q) from this series with an MIC of 0.31 mu g/mL against H37Rv and a cytotoxicity (CC50) against Vero cells of 25 mu g/mL. 20q also had equivalent potency against a panel of single-drug resistant strains of Mtb and remarkably selective activity for Mtb over a panel of other pathogenic bacterial strains. 20q was also negative in a L5178Y MOLY assay, indicating low potential for genetic toxicity. These data along with measurements of the physiochemical properties and pharmacokinetic profile demonstrate that BTOs have the potential to be developed into a new class of antitubercular drugs.